These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30413324)

  • 1. Treatment strategy of end stage renal disease-related hyperparathyroidism before, during, and after the era of calcimimetics.
    van der Plas WY; Engelsman AF; Umakanthan M; Mather A; Sidhu SB; Delbridge LW; Pollock C; Waugh D; Sywak MS; Kruijff S
    Surgery; 2019 Jan; 165(1):135-141. PubMed ID: 30413324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of parathyroidectomy for tertiary hyperparathyroidism with end-stage renal disease: A cost-effectiveness analysis.
    McManus C; Oh A; Lee JA; Hur C; Kuo JH
    Surgery; 2021 Jan; 169(1):94-101. PubMed ID: 32732069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of cinacalcet withdrawal in Australian dialysis patients.
    Ruderman I; Holt SG; Kirkland GS; Maslen S; Hawley CM; Oliver V; Krishnasamy R; Gray NA; Talaulikar GS; Nelson CL; Rajaram Y; Gock H; Au E; Elder GJ; Mainra R; Toussaint ND
    Intern Med J; 2019 Jan; 49(1):48-54. PubMed ID: 29992701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the Introduction of Calcimimetics on Timing of Parathyroidectomy in Secondary and Tertiary Hyperparathyroidism.
    van der Plas WY; Engelsman AF; Özyilmaz A; van der Horst-Schrivers AN; Meijer K; van Dam GM; Pol RA; de Borst MH; Kruijff S
    Ann Surg Oncol; 2017 Jan; 24(1):15-22. PubMed ID: 27459979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing landscape of the treatment of hyperparathyroidism related to end-stage renal disease-can we turn the clock backward?
    Kruijff S; van der Plas WY; Dulfer RR; Vriens MR; van Ginhoven TM; Engelsman AF; Delbridge LW
    Surgery; 2019 Feb; 165(2):289-290. PubMed ID: 30266441
    [No Abstract]   [Full Text] [Related]  

  • 6. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis.
    Brunaud L; Ngueyon Sime W; Filipozzi P; Nomine-Criqui C; Aronova A; Zarnegar R; Kessler M; Frimat L; Ayav C
    Surgery; 2016 Jan; 159(1):183-91. PubMed ID: 26476826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreasing Surgical Management of Secondary Hyperparathyroidism in the United States.
    Fligor SC; Li C; Hamaguchi R; William J; James BC
    J Surg Res; 2021 Aug; 264():444-453. PubMed ID: 33848844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in patients with renal hyperparathyroidism requiring cinacalcet pre-operatively followed by parathyroidectomy.
    Baker D; Sevak S; Callahan RE; Czako PF; Lloyd LR; Nagar S
    Am J Surg; 2019 Jan; 217(1):146-151. PubMed ID: 29929906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical Management of Secondary Hyperparathyroidism and the Role of Surgery: A 5-Year Retrospective Study.
    Sevva C; Divanis D; Tsinari A; Grammenos P; Laskou S; Mantalobas S; Paschou E; Magra V; Kopsidas P; Kesisoglou I; Liakopoulos V; Sapalidis K
    Medicina (Kaunas); 2024 May; 60(5):. PubMed ID: 38792994
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review.
    van der Plas WY; Dulfer RR; Engelsman AF; Vogt L; de Borst MH; van Ginhoven TM; Kruijff S;
    Nephrol Dial Transplant; 2017 Nov; 32(11):1902-1908. PubMed ID: 28402557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
    Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcimimetics versus parathyroidectomy: What is preferable?
    Rroji M; Spasovski G
    Int Urol Nephrol; 2018 Jul; 50(7):1271-1275. PubMed ID: 29532306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroidectomy and Cinacalcet Use in Medicare-Insured Kidney Transplant Recipients.
    Wang AX; Liu S; Montez-Rath ME; Chertow GM; Lenihan CR
    Am J Kidney Dis; 2023 Mar; 81(3):270-280.e1. PubMed ID: 36162617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A patient undergoing chronic dialysis whose renal anemia was successfully corrected by treatment with cinacalcet.
    Oshiro Y; Tanaka H; Okimoto N
    Clin Exp Nephrol; 2011 Aug; 15(4):607-10. PubMed ID: 21455660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
    Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM;
    Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practice variation in the treatment of patients with renal hyperparathyroidism: a survey-based study in the Netherlands.
    Zhang JLH; Appelman-Dijkstra NM; Fu EL; Rotmans JI; Schepers A
    BMC Nephrol; 2021 Apr; 22(1):150. PubMed ID: 33892650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
    Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
    Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients.
    Danese MD; Lubeck D; Belozeroff V; Lin TC; Desai P; Gleeson M; Martin K; Chonchol M
    Am J Nephrol; 2020; 51(10):815-822. PubMed ID: 32966995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of parathyroidectomy on kidney graft function in post-transplant tertiary hyperparathyroidism: a comparative study.
    Frey S; Goronflot T; Blanchard C; Kerleau C; Gourraud PA; Wargny M; Caillard C; Hourmant M; Figueres L; Mirallié É;
    Langenbecks Arch Surg; 2022 Sep; 407(6):2489-2498. PubMed ID: 35596781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.